U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
 - EconoTimes)
SOUTH SAN FRANCISCO, Calif., May 18, 2017 -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that preclinical and clinical data on cerdulatinib in relapsed/refractory b-cell malignancies will be presented at the European Hematology Association (EHA), which is taking place from June 22-25 in Madrid, Spain.
Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancers. Cerdulatinib inhibits two key signaling pathways that promote cancer cell growth in certain hematologic malignancies.
Details regarding the presentations follow.
Oral Presentation Details:
- Presentation Title: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Complete Inhibition of SYK and JAK and Rapid Tumor Responses in a Phase 2 Study in Patients with Relapsed/Refractory B Cell Malignancies
- Presenter: Paul Hamlin, M.D., Memorial Sloan-Kettering Cancer Center
- Abstract Number: EHA22
- Presentation Date and Time: June 25, 2017 from 9:00-9:15 a.m. UTC
- Location: Hall A
Poster Presentation Details:
- Presentation Title: IL-4 Increases Expression of Positive Regulators of BCR Signaling in CLL Which Can Be Overcome by Cerdulatinib
- Presenter: Andrew Steele, Ph.D., Associate Professor, Medicine, University of Southampton
- Abstract Number: P587
- Presentation Date and Time: June 24, 2017 from 5:30 – 6:00 p.m. UTC
- Location: Poster Hall (Hall 7)
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investors: Ana Kapor Portola Pharmaceuticals [email protected] Media: Julie Normart Pure Communications [email protected] 415.946.1087
